The IDM has curated a go-to range of reliable information to guide and assist staff and students during this time of crisis. We are continuously updating the various COVID-19 resources listed on our webpage below.
The IDM - a cross-faculty, multidisciplinary postgraduate health research institute
Based on the UCT Faculty of Health Sciences campus in a 7,100 sqm state-of-the-art facility, we operate in the fields of infectious diseases and molecular medicine.
Clinical research relevant to the needs of Africa's people
The IDM influences health policy and practice by translating our scientific discoveries and applying them in various communities; community relationships and trust are critical.
Capacity building in the IDM
The largest research entity at UCT, the IDM is a national leader in research and health sciences human capital development.
University accredited research institute - Tackling diseases of importance in Africa - Developing people - Impacting health policy and practice
The ground-breaking XACT Model project, which seeks to advance community-based active case finding (ACF) of tuberculosis (TB) using point-of-care molecular technology, has now entered a critical multilayer phase in four sub-Saharan African countries, including South Africa. The project is set to revolutionise TB diagnosis and treatment, and take diagnostic tests out of the laboratory and into the community.
The University of Cape Town’s (UCT) vice-chancellor, Professor Mamokgethi Phakeng, will be one of five speakers at the re-launch of the Life Science Across the Globe (LSAG) as a monthly seminar series.
If the current rate of COVID-19 vaccination continues, global herd immunity will be reached in 2025. Not only would this trajectory create conditions that fuel new variants, but it will leave out the world’s poorest countries.
A One Health approach to vaccine development has many strengths, including for health and food security on the continent. But this country needs to boost its capacity now, write Professor Ed Rybicki and Professor Anna-Lise Williamson from the University of Cape Town (UCT) and Baptiste Dungu, the chief executive of Onderstepoort Biological Products.
